The head of the workshop No. 3 of the FSUE Moscow Endocrine Plant Olga Igorevna Lavrenova devoted more than 22 years to the work at the Enterprise. During this period she witnessed significant events in the history of the Enterprise, which in many respects determined the vector of its development for many years. Before her leaving to a well-deserved rest we asked Olga Igorevna to share her impressions of her work at the FSUE Moscow Endocrine Plant.
Olga Igorevna, you have been working at the FSUE Moscow Endocrine Plant for over 22 years, tell us about the beginning of your work at the Enterprise?
O.I.: In June 1994, at the invitation of Yevgeny Grigoryevich Sharokhin, who was the Director of the FSUE Moscow Endocrine Plant, I joined the Enterprise as the head of the workshop No. 2, which included several sections: ampoule, sublimation, vial, syringe tube production and raw material. The syringe-tube production line occupied a special place, as military drugs - antidotes, promedol, training syringe tubes - were produced on it. Subsequently, the line launched the production of eye drops in a tube dropper.
Did the economic situation in the country of those years influence the operation of the Enterprise?
O.I.: The economic crisis of the 90s in Russia could not but affect the state of production, the Enterprise had to literally “survive” and look for new ways of development. The production of substances from raw materials of animal origin has become unprofitable. In 1994, E.G. Sharokhin, together with the chief engineer of the FSUE Moscow Endocrine Plant Vyacheslav Fedorovich Rudenko, made a bold decision to reprofile production for the production of narcotic analgesics, including in ampoule form for the needs of executive agencies and constituent entities of the Russian Federation, since the basic Soviet enterprise in this industry remained at the territory of Kazakhstan.
The Enterprise constantly develops, as well as, in general, production technologies and equipment. And what features did the production of those years have?
O.I.: At that time the enterprises of our industry just began to become familiar with the rules of Good Manufacturing Practice (GMP) but quality standards always existed. Resources for upgrading of equipment and facilities were limited. In ampoule production the vacuum filling method was still used, which did not allow to provide proper dosing accuracy, which created significant difficulties in the implementation of subject-quantitative accounting of controlled products.
Do I understand correctly that at the beginning of your work at the Enterprise there were two production workshops?
O.I.: Yes, that's right. The first workshop produced ordinary (non-narcotic - note) products in ampoules and vials, and the workshop No. 2, as I said earlier, united a number of sections. In 1995 the decision was made to divide the second workshop into two others: the workshop No. 2 and the workshop No. 3. I was transferred to the position of the head of the workshop No. 3. The third workshop included the production of products in syringe tubes, vials, sublimated forms.
Tell, in what year the Enterprise introduced the tablet production?
O.I.: The decision to introduce drugs in tablet form into production was made in 1997. Before joining the FSUE Moscow Endocrine Plant I worked in the field of tablet production, and therefore, the management of the Enterprise involved me in organization of a new section. Previously acquired experience was useful: in 1999, in collaboration with partners from South Korea, the creation of a tablet production section was completed on the basis of the third workshop. Korean equipment was used in the organization of the line, the installation of clean rooms was also carried out by Korean partners. In 2002 tablet production was separated into a separate structural unit and the fourth workshop was formed.
The Enterprise currently uses the BFS (Blow-Fill-Seal - note) technology in the production of dropper tubes, dropper bottles and syringe tubes. How was the process of introduction of technology into production carried out?
Comment type is not specified in the component properties.